TechnoVax Inc.
Tarrytown
New York
United States
Tel: 914-345-2300
9 articles about TechnoVax Inc.
-
TechnoVax Awarded $1.5 Million NIH Grant to Further Develop a Universal VLP-Based Influenza Vaccine
9/12/2018
TechnoVax, Inc. has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).
-
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
-
TechnoVax Inc. Release: Promising Zika Virus Vaccine Candidate
5/9/2017
-
TechnoVax Inc. Awarded National Institutes of Health (NIH) Grant To Develop A VLP Based Respiratory Syncytial Virus (RSV) Vaccine
6/2/2014
-
TechnoVax Inc. Awarded National Institutes of Health (NIH) Grant to Develop a Universal Flu Vaccine Based on Its Virus-Like-Particle (VLP) Technology
8/1/2013
-
Company Profile for TechnoVax Inc.
10/30/2009
-
TechnoVax Inc. Receives $2.9 Million Grant for Flu and Influenza Virus-Like Particle (VLP) Vaccine Program
10/20/2009
-
TechnoVax Inc. Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate
7/18/2007
-
TechnoVax Inc. Licenses Wyeth's Virus-Like Particle Vaccine Technology
12/11/2006